TH Theratechnologies Inc.

Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its fourth quarter and full year fiscal 2023 ended November 30, on Wednesday, February 21, 2024, at 8:30 a.m. EDT.

Theratechnologies will also provide further information on the Complete Response Letter issued by the U.S. Food and Drug Administration in response to the Company’s supplemental Biologics License Application for the F8 formulation of tesamorelin.

The call will be hosted by Mr. Paul Lévesque, President and Chief Executive Officer. Mr. Lévesque will be joined by other members of the management team, including Senior Vice President and Chief Financial Officer, Mr. Philippe Dubuc, Senior Vice President and Chief Medical Officer, Dr. Christian Marsolais and Global Commercial Officer, Mr. John Leasure, who will be available to answer questions from participants following prepared remarks.

Participants are encouraged to join the call at least ten minutes in advance to secure access. Conference call dial-in and replay information can be found below.

CONFERENCE CALL INFORMATION
Conference Call DateFebruary 21, 2024
Conference Call Time8:30 a.m. EDT
Webcast link
Dial in1-888-317-6003 (toll free) or 1-412-317-6061 (international)
Access Code0664356
CONFERENCE CALL REPLAY
Toll Free1-877-344-7529 (US) / 1-855-669-9658 (Canada)
International Toll1-412-317-0088
Replay Access Code3842515
Replay End DateFebruary 28, 2024
To access the replay using an international dial-in number, please select this link:



An archived webcast will also be available on the Company’s Investor Relations website under ‘.

About Theratechnologies

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at , on SEDAR+ at  and on EDGAR at . Follow Theratechnologies on  and (formerly Twitter). 

Contacts:

Philippe Dubuc

Senior Vice President and Chief Financial Officer



438-315-6608



EN
06/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Theratechnologies Inc.

 PRESS RELEASE

Theratechnologies Reports Financial Results for the Second Quarter 202...

Theratechnologies Reports Financial Results for the Second Quarter 2025 Q2 2025 total revenue of $17.7 million, and $36.8 million for the first six months of Fiscal 2025Positive Adjusted EBITDA1 for the fifth straight quarterSubsequent to quarter end, Theratechnologies entered into a definitive agreement to be acquired by an affiliate of Future Pak MONTREAL, July 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today reported business highlights and financial results fo...

 PRESS RELEASE

Theratechnologies présente ses résultats financiers pour le deuxième t...

Theratechnologies présente ses résultats financiers pour le deuxième trimestre de 2025 Les revenus totaux s’élèvent à 17,7 millions de dollars pour le deuxième trimestre de 2025 et à 36,8 millions de dollars pour le premier semestre de l’exercice 2025Un BAIIA ajusté1 positif a été dégagé pour un cinquième trimestre consécutifAprès la clôture du trimestre, Theratechnologies a conclu un accord définitif visant son acquisition par un membre du même groupe que Future Pak MONTRÉAL, 09 juill. 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Société »...

 PRESS RELEASE

Theratechnologies to Announce Second Quarter 2025 Financial Results

Theratechnologies to Announce Second Quarter 2025 Financial Results MONTREAL, July 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced the Company will report financial results for its second quarter 2025 ended May 31 on Wednesday, July 9, 2025. Given the announcement of July 2, 2025, concerning the , a conference call will not be held. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a specialty biopharmaceutical company focused on the com...

 PRESS RELEASE

Theratechnologies annoncera ses résultats financiers du deuxième trime...

Theratechnologies annoncera ses résultats financiers du deuxième trimestre de l’exercice financier de 2025 MONTRÉAL, 03 juill. 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique au stade commercial, annonce aujourd’hui que la Société dévoilera ses résultats financiers pour le deuxième trimestre de l’exercice financier de 2025, clos le 31 mai 2025, le mercredi 9 juillet 2025. Compte tenu de l'annonce du 2 juillet 2025, concernant , aucune conférence téléphonique ne sera tenue. À propos de The...

 PRESS RELEASE

Theratechnologies enters into Definitive Agreement to be Acquired by C...

Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak Offer of US$3.01 in cash plus one contingent value right for potential additional aggregate payments of up to US$1.19 per shareUpfront and total potential cash consideration represent respectively a 126% and 216% premium to Nasdaq closing price on date prior to announcement of Future Pak’s initial non-binding proposalTransaction with Future Pak represents culmination of sale process whereby Theratechnologies solicited interest from a number of potential counterpartiesBoard unani...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch